Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03674437
Other study ID # 18-294
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date September 11, 2018
Est. completion date September 2024

Study information

Verified date March 2024
Source Memorial Sloan Kettering Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to measure changes in cognitive (mental) function in cancer survivors using a brief, reliable, game-like set of tests that can be completed outside the clinic, as an alternative to traditional neurocognitive assessments. This set of computerized tests, the Cogsuite Assessment, is expected to improve our ability to identify cognitive impairments in people who have been treated for cancer, so that we can (1) learn more about which cognitive functions are affected by cancer treatment, and (2) guide that treatment more effectively.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 441
Est. completion date September 2024
Est. primary completion date September 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 40 Years to 65 Years
Eligibility Inclusion Criteria: For All Participants: - As per medical record or self-report,Female - As per medical record or self-report,Age 40-65 at time of assessment - Score of < 11 on the Blessed Orientation-Memory-Concentration Test (BOMC) - As per self-report, If currently taking psychoactive medications (excluding gabapentin and including but not limited to antidepressants, and anxiolytics), on a daily basis dose must have been stable for at least two months prior to enrollment. - English fluent (as per self-reported fluency of "very well")** ** Language verification: For both patients and controls, prior to enrollment, all will be asked the following two questions by an CRC to verify English fluency necessary for participation in the study: 1. How well do you speak English? (must respond "Very well" when given the choices of Very well, Well, Not well, Not at all, Don"t know, or Refused) 2. What is your preferred language for healthcare? (must respond English) For Patients: - As per medical record or self-report, female - As per medical record or self-report, age 40-65 at time of assessment - As per medical record or self-report, history of AJCC stages 0-3 breast cancer - As per medical record or self-report, greater than six months post-treatment and within 10 years of treatment completion (Note: "post-treatment" refers to completion of surgery, radiation, and/or chemotherapy; a patient who is post-treatment but is on endocrine therapy is still eligible to participate.) For Healthy Controls: - As per medical record or self-report, female - As per medical record or self-report, age 40-65 at time of assessment - As per self-report, no history of cancer except non-melanoma/basal cell skin cancer/squamous cell skin carcinoma, and at the discretion of the PI, early stage secondary cancer diagnoses treated only with surgery (for example, endometrial or cervical cancer) For Healthy 21-25 year old Group: - As per medical record or self-report, age 21-25 at time of assessment - As per self-report, no history of cancer except non-melanoma/basal cell skin cancer/squamous cell skin carcinoma, and at the discretion of the PI, early stage secondary cancer diagnoses treated only with surgery (for example, endometrial or cervical cancer) Exclusion Criteria: For All Participants: - As per medical record or self-report, diagnosis of neurodegenerative disorder that affects cognitive function (e.g. Alzheimer"s disease, Parkinson"s disease, Multiple Sclerosis, Dementia, Seizure Disorders, etc.). - As per medical record or self-report, history of stroke or head injury resulting in a structural lesion on neuropsych imaging, persistent cognitive difficulties impacting work or daily life or required cognitive rehabilitation. - As per self-report, fine motor/motor impairments that interfere with participant"s ability to use a keyboard. - As per medical record or self-report, a diagnosis of a Schizophrenia Spectrum Disorder, substance use disorder, Bipolar Disorder or Schizotypal personality disorder. Schizophrenia Spectrum Disorders include Schizophrenia, Schizophreniform disorder, Schizoaffective disorder, Delusional disorder, Brief psychotic disorder, and Attenuated Psychotic Disorder. - As per medical record or self-report, visual or auditory impairment that would preclude ability to complete the assessments (e.g. history of significant macular degeneration or being unable to correct hearing with hearing aids) - As per self-report, use of methotrexate (Amethopterin, Rhematrex, Trexall) or rituximab (Rituxan) for rheumatoid arthritis, psoriasis or Crohn"s disease, or cyclophosphamide (Cytoxan, Neosar) for Lupus. For Patients only: - As per medical record or self-report, history of another type of cancer, except non-melanoma/basal cell skin cancer/squamous cell skin carcinoma and, at the discretion of the PI, early stage secondary cancer diagnoses treated only with surgery (for example, endometrial or cervical cancer) For all remote administrations: - Minimum Hardware/Software Requirements*: - Processor: Intel Core i3 Processer or greater - Memory: 4GB RAM or greater - Operating System: Recent version of Windows or OS X - Browser: Google Chrome version 64 or higher - Internet Speed: 1.5 Mbps recommended - As per self-report, a quiet space (home or office, door closed) to complete the assessments - Enformia Cognition will provide a web URL (https://www.cogsuite.com/testme) that participants can use to check if they have the minimum requirements. The URL will clearly state if the user has adequate hardware using green and red text and symbols. The test URL will also return a short 5 sequence numeric validation code (xx-xxx) for each browser checked. The validation code will allow Enformia to lookup the specific hardware that was tested. Research Associates can direct prospects to the test web URL during their phone screen.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Traditional Neurocognitive Assessments
Traditional Neurocognitive Assessments given with pen and paper
Online Cognitive Battery (Cogsuite)
Cognition (Cogsuite) for a battery that consists of seven measurements.

Locations

Country Name City State
United States Memorial Sloan Kettering Cancer Center New York New York

Sponsors (3)

Lead Sponsor Collaborator
Memorial Sloan Kettering Cancer Center Dr. Susan Love Research Foundation, ENFORMIA INC.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary validate computerized cognitive measures (Cogsuite Battery) These will include 14 correlations, across the two cohorts and 7 tests (Modified Attention Network Test, N-Back Test, Stop-signal Test, Mental Rotation Test, Verbal Fluency Test, Motor Function Test, and Processing Speed Test). 2 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04049695 - Improving Cognition After Cancer N/A
Completed NCT03696056 - Improving Brain Function After Breast Cancer Study N/A
Active, not recruiting NCT00981305 - Impact of Lactate-Containing Vaginal Lubricant on Sexual Dysfunction in Young Breast Cancer Survivors Phase 3
Active, not recruiting NCT05743023 - Consciousness-based Ayurveda Lifestyle Program for Improving Quality of Life in Survivors of Breast Cancer N/A
Completed NCT02062255 - Impact of COX2 on Sera Biomarkers From Obese Subjects Phase 0
Active, not recruiting NCT04262180 - Physical Activity Promotion for Breast and Endometrial Cancer Survivors N/A
Active, not recruiting NCT04883398 - A Study of Attention and Memory Processes in Breast Cancer Survivors
Completed NCT01217216 - Cancer Survival Through Weight Loss and Exercise N/A
Completed NCT05506189 - Life Style Modification for Breast Canccer Survivors Using Mobile App-based Human Coaching Program
Recruiting NCT03644329 - Effect of Resistance Training Variable Manipulation in Postmenopausal Breast Cancer Survivors. N/A
Active, not recruiting NCT02726763 - Feasibility and Tolerability of Transcranial Direct Current Stimulation With Concurrent Cognitive Training N/A
Recruiting NCT05690295 - Resistance-type Exercise Training in Postmenopausal Women Survivors of Breast Cancer N/A
Recruiting NCT06073717 - Motor-cognitive Training Effects on Cognition in Breast Cancer Survivors: the BRAINonFIT Study (BRAINonFIT). N/A
Not yet recruiting NCT05848141 - Rowing Following Breast Cancer Chemotherapy N/A
Recruiting NCT06334354 - A Study of Changes in Thinking Related to Aging and Cancer in Breast Cancer Survivors (TRAC)
Recruiting NCT03394690 - Effects of Green Coffee Extract Supplementation on Leptin, Ghrelin, Adiponectin,Anthropometric Measurements, Lipid Profile in Breast Cancer Survivors N/A
Completed NCT02753985 - Adherence to Aromatase Inhibitors: The Role of Partners
Active, not recruiting NCT04818359 - Movement and Health Beyond Care (MoviS) N/A
Completed NCT05203029 - Effectiveness of Aerobic Exercises and Laughter Yoga Compared With Yoga in Anxiety/Depression Levels in Breast Cancer N/A
Completed NCT02672189 - Internet-based Cognitive Behavioral Therapy for Breast Cancer Patients With Climacteric Symptoms Phase 3